Effect of Sarpogrelate on Platelet Function in Patients at the Bridging Stage Before Coronary Artery Bypass Grafting
10.3969/j.issn.1000-3614.2014.08.007
- VernacularTitle:冠状动脉旁路移植术前过渡期使用沙格雷酯对血小板功能的影响
- Author:
Meng PENG
;
Xiongjing JIANG
;
Hui DONG
;
Yubao ZOU
;
Ting GUAN
;
Lei SONG
;
Huimin ZHANG
;
Haiying WU
- Publication Type:Journal Article
- Keywords:
Sarpogrelate;
Platelet inhibition rate;
Peripheral artery stent;
Coronary artery bypass grafting
- From:
Chinese Circulation Journal
2014;(8):583-586
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the effect of sarpogrelate on platelet function in patients at the bridging stage before coronary artery bypass grafting (CABG).
Methods: A total of 40 consecutive patients with peripheral artery stent and scheduled for CABG in our hospital from 2011-05 to 2013-04 were enrolled in this study. The patients were randomly divided into 2 groups, Low molecular weight heparin (LMWH) alone group, n=19 and Sarpogrelate+LMWH group, n=21. The medications started at 5-7 days before CABG and stopped at 24 h before CABG. The platelet inhibition rates (platelet aggregation induced by collagen+ serotonin) were examined and compared between 2 groups at the baseline (before randomization), 24h and 1h before CABG respectively.
Results: The platelet inhibition rates were similar between 2 groups at the baseline (87.33 ± 6.82) % vs (86.11 ± 6.87) %, P=0.577 and 1h before CABG (62.60 ± 12.39) % vs (56.19 ± 14.99) %, P=0.148. At 24h before CABG, the platelet inhibition rate in Sarpogrelate+LMWH group was higher than that in LMWH alone group (83.87 ± 8.99)%vs (63.13 ± 10.88)%, P<0.001. Compared with the baseline, the falling range of platelet inhibition was lower in Sarpogrelate+ LMWH group at 24h before CABG, (3.46 ± 6.18) % vs (22.98 ± 9.43) %, P<0.001 and the falling range was similar between 2 groups at 1h before CABG (24.73 ± 14.19)%vs (29.92 ± 14.28)%, P=0.257.
Conclusion: Sarpogrelate + LMWH may result better platelet inhibition rate with quicker recovery of platelet function upon the medication stopping, which might be a feasible management in patients at the bridging stage before CABG.
